About the Company
igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IGMS News
Where IGM Biosciences Stands With Analysts
Across the recent three months, 4 analysts have shared their insights on IGM Biosciences (NASDAQ:IGMS), expressing a variety ...
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today ...
Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet
IGM Biosciences, Inc. (IGMS) closed the last trading session at $12.63, gaining 11% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
IGM Biosciences files patent for anti-pd-L1 antibody for treating diseases mediated by pd-L1 signaling
Discover how IGM Biosciences Inc. is revolutionizing disease treatment with isolated anti-PD-L1 antibodies. Learn about their patent application and method for production.
IGMS Apr 2024 22.500 call
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock ...
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock ...
RBC Capital's Rating Upgrade Propels IGM Biosciences Into Immunology Limelight
RBC Capital upgraded IGM Biosciences Inc (NASDAQ:IGMS), a biotechnology focused on antibody medicines for cancer. RBC analysts upgraded the stock to Outperform from Sector Perform rating with a price ...
Wedbush raises AnaptysBio to outperform, cites upcoming data
Wedbush upped AnaptysBio (ANAB) to outperform, stating it sees upcoming clinical and derivative catalysts driving the shares ...
Selecta Biosciences files patent for enhanced gene therapy using viral vectors and immunosuppressants
Enhance gene expression and reduce immune responses with Selecta Biosciences' patented method using viral vectors and nanocarriers attached to immunosuppressants. Learn more about this innovative ...
IGM Biosciences, Inc.: IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...
Loading the latest forecasts...